# Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

> **NCT07052383** · PHASE1 · RECRUITING · sponsor: **Tcelltech Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Osteosarcoma
- Soft Tissue Sarcoma

## Interventions

- **BIOLOGICAL:** DIT309 cell injection

## Key facts

- **NCT ID:** NCT07052383
- **Lead sponsor:** Tcelltech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2027-10-10
- **Final completion:** 2027-10-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052383, "Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07052383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*